Lineage Cell Financials
| BTX Stock | ILS 210.10 6.70 3.09% |
Lineage |
Understanding current and past Lineage Cell Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Lineage Cell's financial statements are interrelated, with each one affecting the others. For example, an increase in Lineage Cell's assets may result in an increase in income on the income statement.
Please note, the presentation of Lineage Cell's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Lineage Cell's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Lineage Cell's management manipulating its earnings.
Lineage Cell Stock Summary
Lineage Cell competes with Adgar Investments, Oron Group, Scope Metals, Discount Investment, and Arad Investment. BioTime, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing therapies for the treatment of degenerative diseases in the United States and internationally. BioTime, Inc. was founded in 1990 and is headquartered in Alameda, California. BIOTIME INC operates under Biotechnology classification in Israel and is traded on Tel Aviv Stock Exchange. It employs 76 people.| Foreign Associate | USA |
| Instrument | Israel Stock View All |
| Exchange | Tel Aviv Stock Exchange |
| Business Address | 1010 Atlantic Avenue |
| Sector | Healthcare |
| Industry | Biotechnology |
| Benchmark | Dow Jones Industrial |
| Website | www.biotimeinc.com |
| Phone | 510 521 3390 |
| Currency | ILS - Israeli Shekel |
You should never invest in Lineage Cell without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Lineage Stock, because this is throwing your money away. Analyzing the key information contained in Lineage Cell's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Lineage Cell Key Financial Ratios
Lineage Cell's financial ratios allow both analysts and investors to convert raw data from Lineage Cell's financial statements into concise, actionable information that can be used to evaluate the performance of Lineage Cell over time and compare it to other companies across industries.Lineage Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Lineage Cell's current stock value. Our valuation model uses many indicators to compare Lineage Cell value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Lineage Cell competition to find correlations between indicators driving Lineage Cell's intrinsic value. More Info.Lineage Cell Therapeutics is number one stock in price to book category among its peers. It also is number one stock in price to sales category among its peers fabricating about 34.33 of Price To Sales per Price To Book. Comparative valuation analysis is a catch-all model that can be used if you cannot value Lineage Cell by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Lineage Cell's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Lineage Cell Therapeutics Systematic Risk
Lineage Cell's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Lineage Cell volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The function did not generate any output. Please change time horizon or modify your input parameters. The output start index for this execution was one with a total number of output elements of sixty. The Beta measures systematic risk based on how returns on Lineage Cell Therapeutics correlated with the market. If Beta is less than 0 Lineage Cell generally moves in the opposite direction as compared to the market. If Lineage Cell Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Lineage Cell Therapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Lineage Cell is generally in the same direction as the market. If Beta > 1 Lineage Cell moves generally in the same direction as, but more than the movement of the benchmark.
Lineage Cell January 22, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Lineage Cell help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Lineage Cell Therapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Lineage Cell Therapeutics based on widely used predictive technical indicators. In general, we focus on analyzing Lineage Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Lineage Cell's daily price indicators and compare them against related drivers.
| Information Ratio | (0.10) | |||
| Maximum Drawdown | 29.75 | |||
| Value At Risk | (13.91) | |||
| Potential Upside | 9.89 |
Complementary Tools for Lineage Stock analysis
When running Lineage Cell's price analysis, check to measure Lineage Cell's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lineage Cell is operating at the current time. Most of Lineage Cell's value examination focuses on studying past and present price action to predict the probability of Lineage Cell's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lineage Cell's price. Additionally, you may evaluate how the addition of Lineage Cell to your portfolios can decrease your overall portfolio volatility.
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges |